Phathom Pharmaceuticals, Inc. (PHAT) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PHAT Revenue Growth
PHAT Revenue Analysis (2018–2025)
As of May 8, 2026, Phathom Pharmaceuticals, Inc. (PHAT) generated trailing twelve-month (TTM) revenue of $204.9 million, reflecting explosive growth of +104.4% year-over-year. The most recent quarter (Q1 2026) recorded $58.3 million in revenue, up 1.2% sequentially.
Looking at the longer-term picture, PHAT's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $175.1 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including ACAD (+9.9% YoY), SUPN (+16.3% YoY), and PRGO (-3.6% YoY), PHAT has outperformed the peer group in terms of revenue growth. Compare PHAT vs ACAD →
PHAT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PHATCurrent | $205M | +104.4% | - | -91.4% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 IRWD | $296M | +13.8% | -5.3% | 40.1% | |
 PTGX | $46M | -91.5% | +10.0% | -343.6% |
PHAT Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $175.1M | +216.9% | $152.5M | 87.1% | $-159,986,000 | -91.4% |
| 2024 | $55.3M | +8001.5% | $47.3M | 85.6% | $-277,467,000 | -502.2% |
| 2023 | $682K | - | $515K | 75.5% | $-167,312,000 | -24532.6% |
| 2022 | $0 | - | $-620,000 | - | $-172,440,000 | - |
| 2021 | $0 | - | $-521,000 | - | $-135,080,000 | - |
| 2020 | $0 | - | $-300,000 | - | $-125,665,000 | - |
| 2019 | $0 | - | $-8,000 | - | $-106,215,000 | - |
| 2018 | $0 | - | $0 | - | $-1,225,000 | - |
See PHAT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PHAT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PHAT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPHAT — Frequently Asked Questions
Quick answers to the most common questions about buying PHAT stock.
Is PHAT's revenue growth accelerating or slowing?
PHAT revenue is accelerating at +104.4% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $205M. Growth momentum has increased versus prior periods.
What is PHAT's long-term revenue growth rate?
Phathom Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +104.4% is above this long-term average.
How is PHAT's revenue distributed by segment?
PHAT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.